Form 4: Timothy Springer Reports Acquisition of Cartesian Therapeutics Stock and Stock Options

Director and 10% owner Timothy Springer reports acquiring shares and stock options in Cartesian Therapeutics.

Summary

• On January 2, 2025, Timothy A. Springer, a director and 10% owner of Cartesian Therapeutics, acquired 2,600 shares of common stock and 7,800 stock options.
• The common stock was acquired at a price of $0.
• The stock options have an exercise price of $16.93 and expire on January 1, 2035.
• Following the transaction, Springer directly owns 8,510,495 shares of common stock and 7,800 stock options.
• Springer also indirectly owns 330,695 shares through his wife and 529,798 shares through TAS Partners LLC, where he is the managing member.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine filing and doesn't provide substantial information about the company's performance.

Positives

• The acquisition of shares and options by a director and significant shareholder could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the acquisition of shares and options suggests a potentially positive outlook from the reporting person.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders. This filing indicates the transactions of a director and significant shareholder in Cartesian Therapeutics.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates